{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:03:36Z","timestamp":1790136216530,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/igo\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.lanmic.2025.101331","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T22:03:09Z","timestamp":1774648989000},"page":"101331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["WHO assessment of the preclinical antifungal pipeline: evaluating innovation and preparedness in the face of emerging fungal threats"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-6048","authenticated-orcid":false,"given":"Valeria","family":"Gigante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Alm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamarie","family":"Rocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Melchiorri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra M","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2025.101331_bib1","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.lanmic.2025.101331_bib3","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S2213-2600(22)00268-5","article-title":"When disaster strikes fungi take control","volume":"10","author":"Hoenigl","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lanmic.2025.101331_bib4","article-title":"Invasive fungal infections in wars, following explosives and natural disasters: a narrative review","volume":"67","author":"El Eid","year":"2024","journal-title":"Mycoses"},{"key":"10.1016\/j.lanmic.2025.101331_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102325","article-title":"Social determinants of health as drivers of fungal disease","volume":"66","author":"Jenks","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.lanmic.2025.101331_bib6","doi-asserted-by":"crossref","first-page":"e594","DOI":"10.1016\/S2666-5247(24)00039-9","article-title":"Impact of climate change and natural disasters on fungal infections","volume":"5","author":"Seidel","year":"2024","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2025.101331_bib13","article-title":"A second-generation fungerp analog, SCY-247, shows potent in vitro activity against Candida auris and other clinically relevant fungal isolates","volume":"65","author":"Chu","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2025.101331_bib14","author":"Crystal Carter"},{"key":"10.1016\/j.lanmic.2025.101331_bib15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3390\/gels9100787","article-title":"Intravaginal gel for sustained delivery of occidiofungin and long-lasting antifungal effects","volume":"9","author":"Cothrell","year":"2023","journal-title":"Gels"},{"key":"10.1016\/j.lanmic.2025.101331_bib16","author":"Smith"},{"key":"10.1016\/j.lanmic.2025.101331_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw1327","article-title":"Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis","volume":"5","author":"Gebremariam","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.lanmic.2025.101331_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03386-22","article-title":"CotH genes are necessary for normal spore formation and virulence in Mucor lusitanicus","volume":"14","author":"Szebenyi","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.lanmic.2025.101331_bib19","article-title":"Fungal update: Mycology 2025","volume":"6","author":"Dalla Vecchia","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2025.101331_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcyt.2020.11.002","article-title":"Glucuronoxylomannan in the Cryptococcus species capsule as a target for chimeric antigen receptor T-cell therapy","volume":"23","author":"da Silva","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.lanmic.2025.101331_bib21","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.3390\/cells11213386","article-title":"Modification of hinge\/transmembrane and signal transduction domains improves the expression and signaling threshold of GXMR-CAR specific to Cryptococcus spp","volume":"11","author":"Dos Santos","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.lanmic.2025.101331_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.03413-23","article-title":"A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targeting Aspergillus fumigatus","volume":"15","author":"Kumaresan","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.lanmic.2025.101331_bib23","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acsinfecdis.4c00975","article-title":"Synthesis of a new purine analogue class with antifungal activity and improved potency against fungal IP3-4K","volume":"11","author":"Desmarini","year":"2025","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.lanmic.2025.101331_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114776","article-title":"DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs","volume":"196","author":"Meagher","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.lanmic.2025.101331_bib25","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00535-24","article-title":"Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps","volume":"68","author":"Gigante","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.lanmic.2025.101331_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.100992","article-title":"Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses","volume":"6","author":"Melchiorri","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.lanmic.2025.101331_bib28","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1080\/14760584.2023.2279570","article-title":"Vaccine development for pathogenic fungi: current status and future directions","volume":"22","author":"Chechi","year":"2023","journal-title":"Expert Rev Vaccines"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524725002599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666524725002599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:24:22Z","timestamp":1788438262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666524725002599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666524725002599"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2025.101331","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"WHO assessment of the preclinical antifungal pipeline: evaluating innovation and preparedness in the face of emerging fungal threats","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2025.101331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 World Health Organization; licensee Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101331"}}